Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO.
Mitchell B DiccianniKatarzyna KempińskaJon A GangotiAlice L YuLinda S SorkinPublished in: PloS one (2020)
Our results demonstrate that DFMO is an effective agent for reducing anti-GD2 -induced allodynia. Using DFMO in conjunction with dinutuximab may allow for dose escalation in neuroblastoma patients. The reduction in pain may be sufficient to allow new patient populations to utilize this therapy given the more acceptable side effect profile. Thus, DFMO may be an important adjunct to anti-GD2 immunotherapy in addition to a role as a potential anti-cancer therapeutic.
Keyphrases
- neuropathic pain
- end stage renal disease
- high glucose
- diabetic rats
- ejection fraction
- newly diagnosed
- chronic kidney disease
- chronic pain
- peritoneal dialysis
- prognostic factors
- drug induced
- case report
- oxidative stress
- randomized controlled trial
- pain management
- risk assessment
- spinal cord injury
- endothelial cells
- study protocol
- climate change
- human health
- genetic diversity